Compounds > 8,11-dihydroxy-8-angeloyl-11-acetyl-4-guaien-3-one
Page last updated: 2024-11-11

8,11-dihydroxy-8-angeloyl-11-acetyl-4-guaien-3-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

torilin: a sesquiterpene from Torilis japonica; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6450226
MeSH IDM0291333

Synonyms (20)

Synonym
unii-r81x95x49l
5-(1-(acetyloxy)-1-methylethyl)-1,2,4,5,6,7,8,8a-octahydro-3,8-dimethyl-2-oxo-6-azulenyl 2-methyl-2-butenoate (5s-(5alpha,6alpha(z),8alpha,8aalpha))-
2-butenoic acid, 2-methyl-, 5-(1-(acetyloxy)-1-methylethyl)-1,2,4,5,6,7,8,8a-octahydro-3,8-dimethyl-2-oxo-6-azulenyl ester, (5s-(5alpha,6alpha(z),8alpha,8aalpha))-
13018-10-5
8,11-dihydroxy-8-angeloyl-11-acetyl-4-guaien-3-one
r81x95x49l ,
torilin
[(5s,6r,8s,8ar)-5-(2-acetyloxypropan-2-yl)-3,8-dimethyl-2-oxo-4,5,6,7,8,8a-hexahydro-1h-azulen-6-yl] (z)-2-methylbut-2-enoate
torilin [mi]
2-butenoic acid, 2-methyl-, 5-(1-(acetyloxy)-1-methylethyl)-1,2,4,5,6,7,8,8a-octahydro-3,8-dimethyl-
1.beta.-guai-4-en-3-one, 8.beta.,11-dihydroxy-, 11-acetate 2-methylcrotonate, (z)-
26296-53-7
2-butenoic acid, 2-methyl-, (5s,6r,8s,8ar)-5-(1-(acetyloxy)-1-methylethyl)-1,2,4,5,6,7,8,8a-octahydro-3,8-dimethyl-2-oxo-6-azulenyl ester, (2z)-
2-oxo-6-azulenyl ester, (5s-(5.alpha.,6.alpha.(z),8.alpha.,8a.alpha.))-
AKOS032949031
Q27287943
GLXC-16406
2-butenoic acid, 2-methyl-, (5s,6r,8s,8ar)-5-[1-(acetyloxy)-1-methylethyl]-1,2,4,5,6,7,8,8a-octahydro-3,8-dimethyl-2-oxo-6-azulenyl ester, (2z)-
CS-0016428
HY-N1140
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (18.18)18.2507
2000's7 (63.64)29.6817
2010's1 (9.09)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.20 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		1.9910aromatic ether;
nitrile;
polyether;
tertiary amino compound
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		1.9910alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		1.9910taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
finasteride
Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.		2.01103-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
arbutin
hydroquinone O-beta-D-glucopyranoside : A monosaccharide derivative that is hydroquinone attached to a beta-D-glucopyranosyl residue at position 4 via a glycosidic linkage.		2.0510beta-D-glucoside;
monosaccharide derivative		Escherichia coli metabolite;
plant metabolite
sesquiterpenes
[no description available]		3.150
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		2.0510prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
alpha-linolenic acid
linolenic acid : A two-membered subclass of octadecatrienoic acid comprising the (9Z,12Z,15Z)- and (6Z,9Z,12Z)-isomers. Linolenic acids are nutrients essential to the formation of prostaglandins and are also used in making paints and synthetic resins.. linolenate : A polyunsaturated fatty acid anion obtained by deprotonation of the carboxy group of either alpha- or gamma-linolenic acid.		2.0110linolenic acid;
omega-3 fatty acid		micronutrient;
mouse metabolite;
nutraceutical
ConditionIndicatedRelationship StrengthStudiesTrials
Eczema, Atopic
[description not available]		02.610
Innate Inflammatory Response
[description not available]		02.610
Dermatitis, Atopic
A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.		02.610
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.610
Adjuvant Arthritis
[description not available]		02.0810
Hypermelanosis
[description not available]		02.0510
B16 Melanoma
[description not available]		02.0510
Cancer of Skin
[description not available]		02.0510
Skin Neoplasms
Tumors or cancer of the SKIN.		02.0510
Hyperpigmentation
Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.		02.0510
Anoxemia
[description not available]		0210
Angiogenesis, Pathologic
[description not available]		0210
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		0210